Patents by Inventor Andrew J. Dannenberg

Andrew J. Dannenberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240092468
    Abstract: A transportable outboard motor has a midsection and a tiller extending forwardly from the midsection. The tiller is pivotable about a lateral tilt axis into a downward tilt position in which the tiller is oriented transversely to the lateral and longitudinal directions. The tiller in the downward tilt position is configured to permit manual carrying of the transportable outboard motor.
    Type: Application
    Filed: October 17, 2022
    Publication date: March 21, 2024
    Applicant: Brunswick Corporation
    Inventors: Todd D. Dannenberg, Matthew Z. Seta, Scott G. Ahlswede, Gary D. Needham, Robert A. Podell, Andrew J. Przybyl, Matthew S. Dawes
  • Publication number: 20240092470
    Abstract: A transportable outboard motor has a tiller which is pivotable about a lateral tilt axis into a plurality of tilt positions and also pivotable about an axial yaw axis into a plurality of yaw positions. The tiller is pivotable about the axial yaw axis into a straight-ahead position, into a port yaw position which is oriented towards the port side relative to the straight-ahead position, and into a starboard yaw position which is oriented towards the starboard side relative to the straight-ahead position. The tiller is pivotable downwardly about the lateral tilt axis from the port yaw position, and downwardly about the lateral tilt axis from the starboard yaw position. Pivoting the tiller into the plurality of yaw positions creates space for a user to manually grasp a swivel tube and thereby lift the transportable outboard motor from a rear-laydown position.
    Type: Application
    Filed: November 14, 2022
    Publication date: March 21, 2024
    Applicant: Brunswick Corporation
    Inventors: Todd D. Dannenberg, Matthew Z. Seta, Scott G. Ahlswede, Gary D. Needham, Robert A. Podell, Andrew J. Przybyl, Matthew S. Dawes
  • Publication number: 20130324617
    Abstract: Chronic inflammation increases the risk of several epithelial malignancies. The present invention provides methods for determining cancer risk in a patient which comprises detecting the presence of crown-like structures (CLS), methods for treating cancer associated with CLS presence, methods for determining cancer risk in a patient by quantifying the number of CLS in a sample of adipose tissue of the patient, methods of determining prognosis of a patient with breast cancer or other cancers by detecting CLS, and screening methods for anti-cancer agents or agents that inhibit or reduce CLS formation or consequences thereof.
    Type: Application
    Filed: February 11, 2012
    Publication date: December 5, 2013
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, CORNELL UNIVERSITY
    Inventors: Andrew J. Dannenberg, Kotha Subbaramaiah, Clifford Hudis
  • Publication number: 20090156641
    Abstract: The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
    Type: Application
    Filed: February 19, 2009
    Publication date: June 18, 2009
    Inventors: Andrew J. Dannenberg, George Muller
  • Patent number: 7183316
    Abstract: Human papillomavirus (HPV) protein expression is downregulated in patients infected with HPV by administration of PPAR? ligand, selective inhibitor of cyclooxygenase-2 (COX-2), diaryl heterocycle, inhibitor of HPV protein from a natural source and/or certain non-steroidal anti-inflammatory drugs.
    Type: Grant
    Filed: March 14, 2002
    Date of Patent: February 27, 2007
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Andrew J. Dannenberg, Kotha Subbaramaiah
  • Patent number: 7041694
    Abstract: Selective inhibitors of cyclooxygenase-2 are used to treat liver disease and in combination with anti-viral drugs to treat virus-caused liver disorders. Selective inhibitors of cyclooxygenase-2 which also inhibit the synthesis of cyclooxygenase-2 improve over the efficacy of conventional selective inhibitors of cyclooxygenase-2 in the treatment of inflammatory conditions, Alzheimer's disease and cancer.
    Type: Grant
    Filed: December 7, 1998
    Date of Patent: May 9, 2006
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Andrew J. Dannenberg
  • Publication number: 20040077686
    Abstract: The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are known to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
    Type: Application
    Filed: October 7, 2003
    Publication date: April 22, 2004
    Inventors: Andrew J. Dannenberg, George Muller
  • Patent number: 6486203
    Abstract: A patient with an inflammatory disease of the head and neck is treated with a therapeutic amount of a selective inhibitor of cyclooxygenase-2 or a cyclooxygenase-2 inhibitor from a natural source. In one embodiment, a patient with a sore throat caused by tonsillitis or pharyngitis is treated with the topical application of a cyclooxygenase-2 inhibitor from a natural source. In other embodiments, patients with sore throat caused by tonsillitis or pharyngitis or a patient with sinusitis are treated by systemic administration of a selective inhibitor of cyclooxygenase-2. In another embodiment, a patient with periodontitis is treated by administration of a cyclooxygenase-2 inhibitor from a natural source.
    Type: Grant
    Filed: February 7, 2001
    Date of Patent: November 26, 2002
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Andrew J. Dannenberg
  • Publication number: 20020164385
    Abstract: Human papillomavirus (HPV) protein expression is downregulated in patients infected with HPV by administration of PPAR&ggr; ligand, selective inhibitor of cyclooxygenase-2 (COX-2), diaryl heterocycle, inhibitor of HPV protein from a natural source and/or certain non-steroidal anti-inflammatory drugs.
    Type: Application
    Filed: March 14, 2002
    Publication date: November 7, 2002
    Inventors: Andrew J. Dannenberg, Kotha Subbaramaiah
  • Patent number: 6403630
    Abstract: Cancers associated with overexpression of HER-2/neu are treated with a selective inhibitor of cyclooxygenase-2 as the sole treating agent or said inhibitor in combination regimen with HERCEPTIN® and/or standard therapy. Uses include adjuvant therapy for HER-2/neu positive breast cancer and treatment of HER-2/neu positive breast cancer that has metastasized.
    Type: Grant
    Filed: June 22, 2001
    Date of Patent: June 11, 2002
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Andrew J. Dannenberg, Kotha Subbaramaiah
  • Publication number: 20020022627
    Abstract: The present invention provides new methods for inhibiting the activity of the enzyme cycloxygenase-2 (or COX-2). Inhibitors of COX-2 are know to be useful anti-inflammatory, analgesic and anti-angiogenic agents. The compounds in the present case are heterocyclic substituted 4-aminoglutarimides. Methods of using the compounds to inhibit prostaglandin synthesis are claimed.
    Type: Application
    Filed: March 30, 2001
    Publication date: February 21, 2002
    Inventors: Andrew J. Dannenberg, George Muller
  • Patent number: 6291496
    Abstract: Cancer associated with overexpression of class I family of receptor tyrosine kinases, e.g., with overexpresssion of HER-2/neu or overexpression of epidermal growth factor receptor, are treated with strongly binding PPAR&ggr; ligands.
    Type: Grant
    Filed: December 27, 1999
    Date of Patent: September 18, 2001
    Inventors: Andrew J. Dannenberg, Kotha Subbaramaiah
  • Patent number: 6200760
    Abstract: Cells are transfected with a construct containing transcriptional promoter element(s) that have been implicated in carcinogenesis or inflammation ligated to a reporter gene. Determination of inhibition of activation of said promoter element(s) by putative agent indicates the agent is a candidate as a drug or source of a drug for prophylaxis or treatment of cancer or inflammation. The method has particular application to screening agents as candidates for drugs or sources of drugs for prophylaxis or treatment of human disorders caused or mediated by cyclooxygenase-2 and/or matrix metalloproteinases.
    Type: Grant
    Filed: August 13, 1999
    Date of Patent: March 13, 2001
    Assignees: Cornell Research Foundation, Inc., The University of Mississippi
    Inventors: Andrew J. Dannenberg, Kotha J. Subbaramaiah, David S. Pasco
  • Patent number: 5622991
    Abstract: An enteral diet containing fat in an amount to provide from 20 to 50% of total calories, said fat containing less than 15% polyunsaturated fat (e.g., palm oil or medium chain triglycerides) is administered to mediate amelioration of the inflammation associated with the inflammatory liver, pancreatic and intestinal disorders, e.g., to promote healing of the liver in alcoholic hepatitis.
    Type: Grant
    Filed: August 30, 1994
    Date of Patent: April 22, 1997
    Assignees: Cornell Research Foundation, Inc., New England Deaconess Hospital Corp.
    Inventors: Andrew J. Dannenberg, Amin A. Nanji
  • Patent number: 5589504
    Abstract: Based on the discovery that the human bilirubin/phenol UDP-glucuronosyltransferase ugt1 gene complex contains an electrophile responsive element and the knowledge that the rat NADP(H):quinone reductase gene contains an electrophile responsive element, agents which at a concentration of less than 50 .mu.M double the quinone reductase specific activity of Hepa 1clc7 cells, e.g., BHT and sulforaphane, are used for the prophylaxis or treatment of newborn jaundice.
    Type: Grant
    Filed: July 26, 1994
    Date of Patent: December 31, 1996
    Assignees: Cornell Research Foundation, Inc., Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University
    Inventors: Andrew J. Dannenberg, Jayanta R. Chowdhury